

# Fat tissue may play a crucial role in the progression of diabetes, challenging long established notions

October 12 2018

---



Credit: CC0 Public Domain

A new study by Australian researchers, out today, is challenging what we know about the causes of diabetes. The new research points to fat tissue

as a source of disease, and widens our understanding beyond the traditional focus on liver and pancreas as the main culprits.

The findings, uncovered in mice, are published in the high-impact journal *Cell Metabolism*.

## **A startling discovery**

The new research is centred around the surprising finding that protein kinase C epsilon (PKC $\epsilon$ ), known to be involved in diabetes, isn't acting in the [liver](#) or the pancreas as was once assumed.

Researchers have long known that PKC $\epsilon$  is important for the development of diabetes. Mice that have no PKC $\epsilon$  produced anywhere in the body don't develop diabetes-like symptoms—even under conditions where other mice become diabetic.

"We have known for some time that if you remove PKC $\epsilon$  entirely from mice and feed them a [high-fat diet](#) they do not become glucose intolerant. In fact, they are protected from becoming diabetes-like," says Associate Professor Carsten Schmitz-Peiffer (Garvan Institute of Medical Research), who led the research.

Diabetes researchers use a high-fat diet (HFD) to induce type 2 diabetes in mice. Following a HFD, most mice become 'glucose intolerant' - they are unable to control their blood sugar after eating. In particular, the liver becomes 'insulin resistant' - it no longer responds to the pancreatic hormone insulin.

"The big surprise was that when we removed PKC $\epsilon$  production specifically in the liver—the mice were not protected. For over a decade, it's been assumed that PKC $\epsilon$  is acting directly in the liver—by that logic, these mice should have been protected against diabetes."

"We were so surprised by this, that we thought we had developed our mice incorrectly. We confirmed the removal and tested it in several different ways, but they still became glucose intolerant when given a HFD."

## **A new answer: fat**

If not the liver, then where? The hunt was on to determine where PKC $\epsilon$  was working to progress [glucose intolerance](#).

"What we found," explains A/Prof Schmitz-Peiffer, "is that if we removed PKC $\epsilon$  production solely from [fat tissue](#), the mice were protected from becoming glucose intolerant, similar to when we removed PKC $\epsilon$  from the entire animal. So PKC $\epsilon$  isn't progressing diabetes from the liver, but in fact, it is acting from fat [tissue](#) to worsen the disease."

PKC $\epsilon$  has been known to be expressed in multiple tissues, but Prof Schmitz-Peiffer's findings now point to a new function in fat tissue.

## **A changing landscape for fat tissue**

A close examination of the fat tissue revealed a striking difference in the shape and size of the [fat cells](#) in the presence and absence of PKC $\epsilon$ .

"Under the microscope, the fat cells looked very different," A/Prof Schmitz-Peiffer says. "In HFD-fed mice with PKC $\epsilon$  removed from the fat tissue, we saw mostly small, healthy fat cells. And in HFD-fed mice with PKC $\epsilon$  intact—which are glucose intolerant—we saw more of the unhealthy, engorged fat cells, that tend to have less access to oxygen and become inflamed."

For A/Prof Schmitz-Peiffer, it is clear this could have wide-ranging and complex implications for diabetes.

"We know that fat tissue is a lot more than just an inert mass for storing fat," explains A/Prof Schmitz-Peiffer, "it's a very dynamic organ, it sends many messages and releases factors that communicate with the rest of the body, including the liver."

"If PKC $\epsilon$  is changing the nature of fat and affecting the overall health of fat cells, it's changing the types of messages it sends and factors it releases—which could be acting on the liver and possibly other organs to interfere with glucose metabolism."

## **A brake for PKC $\epsilon$ - 10 years in the making**

This discovery is the latest in a long line of contributions made in this field by A/Prof Schmitz-Peiffer.

"10 years ago, we showed that removing PKC $\epsilon$  entirely protected [mice](#) against glucose intolerance. We just never knew where PKC $\epsilon$  was acting. But we knew we might be onto something therapeutically important, if we could find a way to block PKC $\epsilon$ ".

Today, Prof Schmitz-Peiffer is collaborating with Professor Ray Norton and Professor Jonathan Baell at the Fragment Based Drug Discovery Platform at the Monash Institute of Pharmaceutical Sciences to develop an orally available peptide that can disrupt PKC $\epsilon$  activity.

"These results give us an even better idea about how to target PKC $\epsilon$  to develop the most effective treatments possible. And therapeutically targeting PKC $\epsilon$  would be a new possible approach for [diabetes](#) treatment."

Provided by Garvan Institute of Medical Research

Citation: Fat tissue may play a crucial role in the progression of diabetes, challenging long established notions (2018, October 12) retrieved 23 April 2024 from <https://medicalxpress.com/news/2018-10-fat-tissue-crucial-role-diabetes.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.